COGNITION THERAPEUTICS INC. - COMMON STOCK

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease

12 8 2025 13:00:26 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

07 8 2025 13:00:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

29 7 2025 04:30:23 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease

21 7 2025 04:30:37 提供 Nasdaq GlobeNewswire

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

16 7 2025 04:30:51 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease

10 7 2025 04:30:53 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target

01 7 2025 04:30:23 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

25 6 2025 04:30:23 提供 Nasdaq GlobeNewswire

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

03 6 2025 04:30:02 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

28 5 2025 04:30:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

09 5 2025 04:30:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

08 5 2025 04:30:31 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

07 5 2025 04:30:15 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes

01 4 2025 04:30:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025

25 3 2025 04:30:57 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

20 3 2025 04:00:26 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

13 3 2025 13:05:30 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

12 3 2025 13:05:04 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

10 3 2025 04:30:44 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

27 2 2025 04:30:08 提供 Nasdaq GlobeNewswire